PCRX
HEALTHCAREPacira BioSciences, Inc.
AI Insight
What's Moving PCRX Today?
No stock-specific AI insight has been generated for PCRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$18.80$27.64
$24.10
Fundamentals
Market Cap$925M
P/E Ratio180.9
EPS$0.13
Dividend Yield—
Dividend / Share—
ROE0.7%
Profit Margin0.7%
Debt / Equity—
Trading
Volume126K
Avg Volume (10D)—
Shares Outstanding39.3M
PCRX News
23 articles- Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsightGlobeNewswire Inc.·Jun 15, 2026
- Pacira BioSciences (NASDAQ:PCRX) Stock Crosses Below 50 Day Moving Average - Should You Sell?MarketBeat·Jun 12, 2026
- Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual MeetingYahoo Finance·Jun 9, 2026
- Egan-Jones Recommends Pacira Shareholders Support All Management NomineesYahoo Finance·Jun 5, 2026
- Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual MeetingYahoo Finance·Jun 4, 2026
- Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director NomineesYahoo Finance·Jun 1, 2026
- Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director NomineesYahoo Finance·May 28, 2026
- DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTIONYahoo Finance·May 28, 2026
- Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the DetailsYahoo Finance·May 27, 2026
- Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified NomineesYahoo Finance·May 27, 2026
- Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder ArthroplastyYahoo Finance·May 27, 2026
- Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property StrategyYahoo Finance·May 26, 2026
- A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLCYahoo Finance·May 21, 2026
- Doma Perpetual Buys Another $5.6 Million of Nomad Foods With the Stock Down 20% in 2026Motley Fool·May 21, 2026
- DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira BiosciencesYahoo Finance·May 20, 2026
- Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All StockholdersYahoo Finance·May 20, 2026
- Pacira BioSciences' (NASDAQ:PCRX) Performance Is Even Better Than Its Earnings SuggestYahoo Finance·May 13, 2026
- DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board CandidatesYahoo Finance·May 13, 2026
- Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare ConferencesYahoo Finance·May 13, 2026
- Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board NomineesYahoo Finance·May 12, 2026
- Earnings call transcript: Pacira BioSciences Q1 2026 earnings exceed forecasts By Investing.comInvesting.com Canada·May 9, 2026
- Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·May 8, 2026
- Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty ProceduresGlobeNewswire Inc.·Apr 13, 2026
All 23 articles loaded
Price Data
Open$23.74
Previous Close$23.51
Day High$24.19
Day Low$23.54
52 Week High$27.64
52 Week Low$18.80
52-Week Range
$18.80$27.64
$24.10
Fundamentals
Market Cap$925M
P/E Ratio180.9
EPS$0.13
Dividend Yield—
Dividend / Share—
ROE0.7%
Profit Margin0.7%
Debt / Equity—
Trading
Volume126K
Avg Volume (10D)—
Shares Outstanding39.3M
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—